Morgan Stanley analyst Mark Purcell resumed coverage of Sanofi with an Overweight rating and EUR 95 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNY:
- Sanofi does not intend to make offer for Horizon Therapeutics
- Revolution to regain rights to RMC-4630 following Sanofi deal termination
- Sanofi terminates SHP2 Inhibitor development pact with Revolution Medicines
- Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler
- Florida district court grants Sanofi, GSK summary judgment of Zantac suits